Our study highlights the potential of RFNG phosphorylation as a biomarker for predicting the efficacy of oxaliplatin chemotherapy and suggests that targeting RFNG could be a promising strategy for overcoming chemoresistance in CRC. This evidence concerns the gene RFNG and colorectal carcinoma.